Comparative efficacy of acid-suppressive and gastroprotective agents in patients with coronary heart disease on antiplatelet therapy: A systematic review and network meta-analysis
In brief
Vonoprazan ranked highest, with 95% lower estimated ulcer risk than placebo
In a network analysis of 20 randomized trials, vonoprazan was linked to an estimated 95% lower risk of peptic ulcers than placebo in patients with coronary heart disease taking antiplatelet therapy; proton pump inhibitors also reduced ulcer risk. Vonoprazan's apparent edge rests on few trials and indirect comparisons, so direct studies are needed before concluding it outperforms proton pump inhibitors.
- Journal
- Therapeutic advances in gastroenterology (Q1)
- Published
- 7 October 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Yujie Zhang, Junyan Zhang, Xiaoli Fan, Xiaoyan Ao, Yong He, Zhongxiu Chen, et al.
- PMID
- 43036424
- DOI
- 10.1177/17562848261492836
Why clinicians should know about it
- Picked for Gastroenterology (top studies of the week, 22 November 2026): Evidence synthesis addresses prevention of antiplatelet-associated GI bleeding
Abstract
BACKGROUND: Gastrointestinal complications remain an important clinical concern in patients with coronary heart disease (CHD) receiving antiplatelet therapy, and the comparative effectiveness of available acid-suppressive and gastroprotective strategies in this population remains uncertain. OBJECTIVES: To compare the efficacy of acid-suppressive agents and gastric mucosal protectants for preventing peptic ulcer occurrence and gastrointestinal bleeding in patients with CHD receiving antiplatelet therapy. DESIGN: Systematic review and network meta-analysis of randomized controlled trials. DATA SOURCES AND METHODS: PubMed, Embase, the Cochrane Library, and Ovid MEDLINE were searched from inception to May 29, 2024. Eligible trials enrolled patients receiving antiplatelet therapy, predominantly low-dose aspirin or dual antiplatelet therapy, and compared PPIs, H2RAs, P-CAB, gastric mucosal protectants, or placebo. Relative risks were synthesized using random-effects network meta-analysis, with assessment of risk of bias, inconsistency, transitivity, and small-study effects. RESULTS: Twenty randomized controlled trials were included. Acid-suppressive agents were generally more effective than gastroprotective agents in preventing gastrointestinal complications. For peptic ulcer occurrence, the estimated RRs versus placebo were 0.05 for vonoprazan, 0.14 for PPIs, and 0.48 for famotidine, whereas gastroprotective agents showed less consistent protective effects. For gastrointestinal bleeding, vonoprazan also showed favorable trends. However, the evidence for P-CAB was based on a limited number of trials, and its apparent advantage over PPIs should therefore be interpreted cautiously. CONCLUSION: Acid-suppressive therapies may be preferable to gastroprotective agents for preventing gastrointestinal injury in patients with CHD receiving antiplatelet therapy. P-CAB ranked highest in the current network, but this finding should be considered hypothesis-generating until confirmed by adequately powered direct comparative trials against PPIs.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.